1. Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive review
2. Global Initiative for Asthma (GINA) . 2022 GINA Report, Global Strategy for Asthma Management and Prevention. Available from https://ginasthma.org/gina-reports/
3. US Food and Drug Administration (FDA) . Updated Information on Leukotriene Inhibitors: Montelukast (Marketed as Singulair), Zafirlukast (Marketed as Accolate), and Zileuton (Marketed as Zyflo and Zyflo CR). www.pdr.net/fda-drug-safety-communication/singulair?druglabelid=390. Date last updated: 28 August 2009. Date last accessed: 29 November 2020.
4. Joint statement on FDA investigation of Singulair from the ACAAI and AAAAI;Sampson;Eur Ann Allergy Clin Immunol,2020
5. US Food and Drug Administration (FDA) . FDA Requires Stronger Warning About Risk of Neuropsychiatric Events Associated with Asthma and Allergy Medication Singulair and Generic Montelukast. www.fda.gov/news-events/press-announcements/fda-requires-stronger-warning-about-risk-neuropsychiatric-events-associated-asthma-and-allergy. Date last updated: 4 March 2020. Date last accessed: 19 June 2020.